Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:30 AM ET Form 4
Insider Buying Perspective Therapeutics, Inc. CATX

Perspective Therapeutics Director Frank Morich Buys $15K of Stock

Frank Morich, Director, bought 15,000 shares of Perspective Therapeutics, Inc. at $0.9971 a share, worth $15K in total on Nov 12, 2026. Shares held after the trade: 15,000.

Value
$15K
Shares
15,000
Price
$0.9971
Role
Director
Trade date
Nov 12, 2026
8:30 AM ET Form 4
Insider Buying Perspective Therapeutics, Inc. CATX

Perspective Therapeutics Director Lori A. Woods Buys $20K of Stock

Lori A. Woods, Director, bought 23,750 shares of Perspective Therapeutics, Inc. at $0.8438 a share, worth $20K in total on Nov 12, 2026. Shares held after the trade: 28,557 (+494.1%).

Value
$20K
Shares
23,750
Price
$0.8438
Role
Director
Holding change
+494.1%
Trade date
Nov 12, 2026
8:29 AM ET 8-K
Financial Results HeartCore Enterprises, Inc. HTCR

HeartCore Enterprises Financial Results

HeartCore Enterprises reported Q3 2026 financial results, showing a significant revenue decline to $0.16 million from $1.2 million year-over-year due to fewer successful client IPOs. The company completed its strategic exit from software development services by divesting its interest in HeartCore Luvina to focus on its Go IPO consulting and capital markets advisory business.

Term
Q3 2026

“With the transfer of our interest in HeartCore Luvina completed during the third quarter, we have concluded the portfolio optimization we began earlier this year. HeartCore now operates as a focused Go IPO consulting, capital markets advisory, and financial services company, which we believe allows us to direct management attention and capital toward the areas where we see the greatest long-term opportunity.”

Sumitaka Kanno, HeartCore CEO

“The Nasdaq listing environment remains selective, and a number of our clients have extended their IPO timelines as they work to satisfy stricter exchange and regulatory requirements. We continue to prioritize clients that we believe demonstrate stronger fundamentals, organizational readiness, and a clear path to a U.S. listing, and we are cautiously optimistic that this disciplined approach will support a higher-quality pipeline over time.”

Sumitaka Kanno, HeartCore CEO
8:29 AM ET Form 4
Insider Buying PureCycle Technologies, Inc. PCT

PureCycle Technologies Executive Chairman Fernando Musa Buys $98.5K of Stock

Fernando Musa, Executive Chairman, bought 57,600 shares of PureCycle Technologies, Inc. at $1.71 a share, worth $98.5K in total on Nov 13, 2026. Shares held after the trade: 386,957 (+17.5%).

Value
$98.5K
Shares
57,600
Price
$1.71
Role
Executive Chairman
Holding change
+17.5%
Trade date
Nov 13, 2026
8:24 AM ET 8-K
Shareholder Meeting Powerfleet, Inc. AIOT

Powerfleet Shareholder Meeting

Powerfleet, Inc. elected Eddie Capel and John Strosahl to its Board of Directors as independent directors, effective November 16, 2026. Both appointees bring extensive enterprise software and SaaS leadership experience, having previously served as CEOs of Manhattan Associates and Jamf, respectively. The appointments are part of the company's strategy to scale its AIoT software-as-a-service platform.

8:21 AM ET 8-K
Leadership Change Cadre Holdings, Inc. CDRE

Cadre Holdings Leadership Change

Blaine Browers has resigned as Chief Financial Officer of Cadre Holdings, effective December 31, 2026, to pursue other opportunities. The company has appointed Chad Appleby, the current Vice President & Treasurer, to serve as interim CFO starting January 1, 2027, while a permanent successor is sought.

8:18 AM ET 8-K
Financial Results Widepoint Corp WYY

Widepoint Financial Results

WidePoint Corporation reported financial results for the third quarter ended September 30, 2026, and provided an update on its DHS CWMS 3.0 contract status. Despite a GAO protest setback, the company was awarded 40 new and replacement task orders valued at $33.7 million during the quarter under existing bridge contracts.

Term
Q3 2026

“I want to acknowledge that the last few months have presented challenges and outcomes that fell short of what we had envisioned for our DHS program. As you know, the Government Accountability Office, or the GAO's decision to sustain the protest filed regarding the pending CWMS 3.0 award, while not unprecedented, was still an unexpected setback.”

Jin Kang, Chief Executive Officer, President and Director

“While delays and setbacks are frustrating, we are well-positioned to withstand near-term headwinds as we await a decision from DHS.”

Jin Kang, Chief Executive Officer, President and Director
8:17 AM ET Form 4
Insider Buying Dynex Capital Inc DX

Dynex Capital Co-CEO & Chairman of the Board Byron L. Boston Buys $50K of Stock

Byron L. Boston, Co-CEO & Chairman of the Board, bought 4,965 shares of Dynex Capital Inc at $10.07 a share, worth $50K in total on Nov 13, 2026. Shares held after the trade: 897,712 (+0.6%).

Value
$50K
Shares
4,965
Price
$10.07
Role
Co-CEO & Chairman of the Board
Holding change
+0.6%
Trade date
Nov 13, 2026
8:17 AM ET 8-K
Loan & Debt Everforth Inc EFOR

Everforth $500M Debt Financing

Everforth Inc announced a private offering of $500 million in aggregate principal amount of unsecured senior notes due 2031. The company intends to use the net proceeds, along with revolving credit facility borrowings, to redeem its outstanding 4.625% Senior Notes due 2028 and pay related fees.

Value
$500M
Term
through 2031
8:17 AM ET Form 4
Insider Buying TriSalus Life Sciences, Inc. TLSI

TriSalus Life Sciences Insider Mats Wahlstrom Buys $112K of Stock

Mats Wahlstrom bought 50,000 shares of TriSalus Life Sciences, Inc. at $2.24 a share, worth $112K in total on Nov 12, 2026. Shares held after the trade: 197,555 (+33.9%).

Value
$112K
Shares
50,000
Price
$2.24
Holding change
+33.9%
Trade date
Nov 12, 2026
8:16 AM ET Form 4
Insider Buying Dynex Capital Inc DX

Dynex Capital Co-CEO and President Smriti Laxman Popenoe Buys $25.7K of Stock

Smriti Laxman Popenoe, Co-CEO and President, bought 2,600 shares of Dynex Capital Inc at $9.90 a share, worth $25.7K in total on Nov 13, 2026. Shares held after the trade: 543,698 (+0.5%).

Value
$25.7K
Shares
2,600
Price
$9.90
Role
Co-CEO and President
Holding change
+0.5%
Trade date
Nov 13, 2026
8:16 AM ET 10-Q
Financial Results Alx Oncology Holdings Inc ALXO

Alx Oncology Holdings Q3 2026 Results: Net Loss of $21.8M, Loss Narrows

ALX Oncology reported a net loss of $57.7 million for the nine months ended September 30, 2026, an improvement from the $78.8 million loss in the prior year period. The company significantly strengthened its balance sheet through equity offerings, increasing total stockholders' equity to $125.9 million from $26.0 million at the end of 2025.

Key figure
Net loss $21.8M
8:16 AM ET 10-Q
Financial Results US Alliance Corp

US Alliance Q3 2026 Results: Net Loss of $529K, Loss Widens

US Alliance Corp reported a net loss of $820,543 for the nine months ended September 30, 2026, compared to a loss of $795,892 in the prior year period. Total assets remained stable at $149.4 million, while the company saw a significant shift in its investment portfolio toward mortgage loans and a decrease in cash and cash equivalents.

Key figure
Net loss $529K
8:16 AM ET 10-Q
Financial Results Neumora Therapeutics, Inc. NMRA

Neumora Therapeutics Q3 2026 Results: Net Loss of $34.4M, Loss Narrows

Neumora Therapeutics reported a net loss of $34.4 million for the third quarter of 2026, an improvement from the $56.8 million loss in the prior year period. The company's cash and cash equivalents decreased significantly to $85.7 million as of September 30, 2026, compared to $182.5 million at the end of 2025, while total stockholders' equity fell to $18.6 million.

Key figure
Net loss $34.4M
8:16 AM ET 8-K
Financial Results Virtuix Holdings Inc. VTIX

Virtuix Holdings Financial Results

Virtuix Holdings reported Q2 fiscal 2027 financial results featuring 55% sequential revenue growth to $1.2 million, driven by a 105% increase in Omni One revenue following its launch for Meta Quest. The company also announced a non-binding letter of intent to acquire defense technology firm STS International for approximately $12 million to expand its presence in the government and defense sectors.

Term
Q2 2027
8:16 AM ET 8-K
Clinical Trial Data CG Oncology, Inc. CGON

CG Oncology Clinical Trial Data

CG Oncology announced positive topline results from its Phase 3 PIVOT-006 registrational trial of cretostimogene in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer (NMIBC). The trial met its primary endpoint, showing a 68% reduction in the risk of recurrence (hazard ratio of 0.32) compared to the control arm, with no Grade 3 or higher treatment-related adverse events reported.

8:16 AM ET 8-K
Investor Presentation Acnb Corp ACNB

Acnb Investor Presentation

ACNB Corporation has furnished a formal investor presentation deck for the third quarter of 2026. The presentation provides strategic highlights and financial data for the company and its subsidiaries, ACNB Bank and ACNB Insurance Services, to be used in meetings with investors and analysts.

8:15 AM ET 10-Q
Financial Results Tancheng Group Co., Ltd. QSJC

Tancheng Group Co Q3 2026 Results: Net Loss of $89.7K, Loss Widens

Tancheng Group Co., Ltd. reported zero revenue for the nine months ended September 30, 2026, as it pivoted from product sales to the development of a cultural tourism project. The company recorded a net loss of $338,896 for the period and maintains a significant accumulated deficit of $2.4 million, raising concerns about its ability to continue as a going concern.

Key figure
Net loss $89.7K
8:13 AM ET 8-K
Financial Results Dawson Geophysical Co DWSN

Dawson Geophysical Financial Results

Dawson Geophysical reported third quarter 2026 financial results, including fee revenue of $10.8 million and a net loss of $5.2 million. The company noted that two large channel crew jobs were delayed from Q3 into Q4 due to government permitting issues, but highlighted a strengthened backlog and renewed demand for seismic data acquisition in North America.

“Although our financial performance fell short of our expectations in the third quarter, I cannot be more excited about how this Company is positioned to capitalize on the renewed demand for seismic data acquisition services in North America. We are observing increased demand in Canada and in the United States across the oil and gas space and in other non-traditional markets, such as Carbon Capture, Utilization, and Storage (“CCUS”) and geothermal, and we are scheduled to start our first geothermal data acquisition in November.”

Tony Clark, Dawson’s President and CEO

“I evaluate the Company’s performance over the long term rather than quarterly, and 2026 will be the third year in a row of increasing top-line revenue, improved gross margins and higher Adjusted EBITDA, and I expect that to continue in 2027.”

Tony Clark, Dawson’s President and CEO
8:13 AM ET 10-Q
Financial Results Idaho Strategic Resources, Inc. IDR

Idaho Strategic Resources Q3 2026 Results: Net Income $2.64M, Down 11.2% YoY

Idaho Strategic Resources reported a significant increase in nine-month revenue to $37.1 million in 2026, up from $27.8 million in 2025, driven by product sales. Net income attributable to the company rose to $12.7 million for the nine-month period, while the company transitioned its investment strategy by transferring $64.2 million of US treasury notes from held-to-maturity to available-for-sale.

Key figure
Net income $2.64M · -11.2% YoY
8:13 AM ET 8-K
Financial Results Veritone, Inc. VERI

Veritone Financial Results

Veritone reported Q3 2026 revenue of $18.6 million, a 30% year-over-year decrease, and a net loss of $19.2 million. Alongside results, the company announced a debt exchange for $38.7 million of convertible notes and a $40 million senior secured term loan commitment from Blue Torch Capital to improve its liquidity position.

Term
Q3 2026

“We have spent the majority of fiscal 2026 taking actions to put Veritone in a stronger financial and operational position. With our newly announced convertible notes exchange and commitment letter, combined with our recent cost reduction efforts, we are on a clear path to greatly improve our financial position and ability to execute our operating model and product strategy.”

Ryan Steelberg, President and Chief Executive Officer of Veritone
8:13 AM ET 8-K
Loan & Debt Akebia Therapeutics, Inc. AKBA

Akebia Therapeutics $140M Debt Financing with Symbiotic Capital Opportunities Holding, L.P.

Akebia Therapeutics entered into a $140 million senior secured term loan facility with Symbiotic Capital, consisting of a $60 million initial tranche and $80 million in discretionary tranches. The company used the initial proceeds to repay its existing $55 million debt facility with BlackRock (Kreos). The new facility features a 60-month interest-only period with a maturity date of November 12, 2031.

Value
$140M
Counterparty
Symbiotic Capital Opportunities Holding, L.P.
Term
5 years
8:11 AM ET 8-K
Capital Raise Surrozen, Inc. SRZN

Surrozen Capital Raise of $60M

Surrozen, Inc. entered into an underwriting agreement for a public offering of 1,894,540 shares of common stock at a price of $31.67 per share. The company expects to receive gross proceeds of approximately $60 million from the offering, which is scheduled to close on November 16, 2026.

Value
$60M
Counterparty
Morgan Stanley & Co. LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co.
8:11 AM ET 8-K
Financial Results Alx Oncology Holdings Inc ALXO

Alx Oncology Holdings Financial Results

ALX Oncology reported third quarter 2026 financial results, ending the period with $147.2 million in cash and investments, which is expected to fund operations through the first half of 2028. The company highlighted clinical progress for evorpacept and ALX2004, with topline data from the ASPEN-09-Breast trial now expected in the second half of 2027.

“Throughout the third quarter, we continued to make significant progress across both the ASPEN-09-Breast and ALX2004 clinical trials. The recent publication of ASPEN-06 results in Nature Medicine further reinforces the promise of evorpacept and our biomarker-driven development strategy.”

Jason Lettmann, Chief Executive Officer of ALX Oncology
8:11 AM ET 10-Q
Financial Results Apnimed, Inc. APMD

Apnimed Q3 2026 Results: Net Loss of $29.5M, Loss Widens

Apnimed, Inc. is a late-stage clinical pharmaceutical company focused on its lead product candidate, Oxnimbi, which has completed Phase 3 clinical trials. The company reports significant operating losses since inception and anticipates requiring substantial additional funding to support its commercialization efforts and regulatory approval processes.

Key figure
Net loss $29.5M
8:10 AM ET 8-K
Clinical Trial Data Corbus Pharmaceuticals Holdings, Inc. CRBP

Corbus Pharmaceuticals Holdings Clinical Trial Data

Corbus Pharmaceuticals announced positive Phase 1b clinical trial data for CRB-913, an oral non-incretin therapy for obesity, presented at ObesityWeek 2026. The CANYON-1 trial demonstrated statistically significant weight loss across all doses, with the 60 mg cohort achieving a 5% mean weight loss at 12 weeks and a favorable safety profile with low discontinuation rates.

Term
16 weeks

“In the CANYON-1 trial, CRB-913 was safe and well tolerated while demonstrating clinically meaningful weight loss as an oral therapy via a distinct, non-incretin mechanism. We’re encouraged that CRB-913 has emerging potential as a novel therapeutic option for people living with obesity and look forward to future development.”

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus
8:09 AM ET Form 4
Insider Buying Csquare, Inc. CSQR

Csquare Insider Terri Pizzuto Buys $33.9K of Stock

Terri Pizzuto bought 2,000 shares of Csquare, Inc. at $16.96 a share, worth $33.9K in total on Nov 13, 2026. Shares held after the trade: 5,600 (+55.6%).

Value
$33.9K
Shares
2,000
Price
$16.96
Holding change
+55.6%
Trade date
Nov 13, 2026
8:09 AM ET 8-K
Stock Buyback News Corp NWSA

News Stock Buyback Update

News Corp provided a daily update on its existing $1 billion stock repurchase program as required by Australian Securities Exchange (ASX) rules. The filing includes daily buy-back notifications for the company's Nasdaq-listed Class A and Class B common stock. No ASX-listed CDIs are being repurchased under this program.

8:09 AM ET 8-K
Contract Win Corvex, Inc. MOVE

Corvex Wins $103M Contract from scaled AI inference platform

Corvex, Inc. signed a definitive three-year, $103 million take-or-pay agreement to provide NVIDIA Blackwell computing capacity to a scaled AI inference platform. The deployment, which includes over 1,000 NVIDIA HGX B200 GPUs, is expected to cost $78 million and will be funded primarily through a $26 million customer prepayment and $38 million in non-recourse debt financing.

Value
$103M
Counterparty
scaled AI inference platform
Term
3 years
8:09 AM ET 8-K
Financial Results Iambic Therapeutics, Inc. IAM

Iambic Therapeutics Financial Results

Iambic Therapeutics reported third quarter 2026 financial results, highlighting a pro-forma cash position of $455 million following its IPO and upfront payments from AbbVie. The company reported year-to-date collaboration revenue of approximately $24 million and total operating expenses of $108 million. Key operational milestones included the launch of its Enchant v3 AI model and positive Phase 1/2 data for its HER2 inhibitor, IAM1363.

Term
Q3 2026

“Iambic’s mission is to make better technology for better medicines, and we believe that the past several months showed that at work across every part of our business. At ESMO, our updated clinical data showed the intracranial activity and tolerability for IAM1363, and we are preparing to start a registrational trial in 2027, subject to regulatory approval. We submitted the IND and have received a Safe-to-Proceed Letter for a Phase 1/2 trial for IAM217, our second wholly owned and platform-discovered candidate, with an anticipated IND submission for IAM-C1, our CDK2/4 inhibitor, close behind. We launched Enchant v3, a huge advance in the core AI technology that underpins our molecular superintelligence platform, and AbbVie and Bayer each chose to bring our platform to bear on their own discovery work through new Iambic partnerships. Our IPO gives us the resources to advance our pipeline through major inflection points and to keep scaling the platform behind it.”

Tom Miller, PhD, Co-Founder & CEO of Iambic

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.